§ 01 Overview
Overview
Dual glucagon/GLP-1 receptor agonist from Boehringer Ingelheim; holds FDA Breakthrough Therapy designation for MASH with fibrosis.
Phase 2 obesity and Phase 2 MASH data published 2023–2024. SYNCHRONIZE-1 Phase 3 ongoing.
§ 02 Mechanism
Mechanism of action
Survodutide is a weekly SC peptide that co-agonizes glucagon and GLP-1 receptors. Glucagon activity is proposed to raise hepatic energy expenditure while GLP-1 suppresses appetite, with particular rationale in metabolic-associated steatohepatitis (MASH).
- 01Weight loss comparable to tirzepatide-class in Phase 2
- 02FDA Breakthrough Therapy designation for MASH (Sept 2024)
- 03Hepatic fat reduction and fibrosis signal
§ 03 Dosing
Dosing protocol
Standard Protocol
- Dose Range
- 0.6 – 6 mg weekly (trial)
- Route
- SubQ
- Frequency
- Weekly
- Cycle
- Phase 3 titration
§ 04 Evidence
Evidence & research
Phase 2 obesity and Phase 2 MASH data published 2023–2024. SYNCHRONIZE-1 Phase 3 ongoing.
FDA Status
Investigational. FDA Breakthrough Therapy designation (MASH).
§ 06 News
In the news
8 articles from the last 12 months · updates hourly
Retatrutide and Survodutide Make Inroads Into Weight Loss for Diabetic Patients - TCTMD.com
Retatrutide and Survodutide Make Inroads Into Weight Loss for Diabetic Patients TCTMD.com
Survodutide delivers weight loss and glycemic gains in phase 3 trial - PharmaTimes
Survodutide delivers weight loss and glycemic gains in phase 3 trial PharmaTimes
Survodutide Lowers Weight and A1c in Adults With Obesity/T2D - Medscape
Survodutide Lowers Weight and A1c in Adults With Obesity/T2D Medscape
Survodutide delivers up to 13.1% weight loss in phase 3 obesity and diabetes trial - Pharmafile
Survodutide delivers up to 13.1% weight loss in phase 3 obesity and diabetes trial Pharmafile
Survodutide Achieves Significant Weight Loss and HbA1c Reduction in Adults With Obesity and Type 2... - Medical Dialogues
Survodutide Achieves Significant Weight Loss and HbA1c Reduction in Adults With Obesity and Type 2... Medical Dialogues
Boehringer Ingelheim's survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetes - PR Newswire Canada
Boehringer Ingelheim's survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetes PR Newswire Canada
Survodutide Meets Co-Primary Weight Loss Endpoints in Phase 3 SYNCHRONIZE-2 Trial in Obesity and Type 2 Diabetes - BioPharm International
Survodutide Meets Co-Primary Weight Loss Endpoints in Phase 3 SYNCHRONIZE-2 Trial in Obesity and Type 2 Diabetes BioPharm International
Weekly Recap: Buyback status and Boehringer survodutide results - TradingView
Weekly Recap: Buyback status and Boehringer survodutide results TradingView
§ 07 Sourcing
Sourcing & supply
Regulatory status
Investigational, no compounding path
Currently in active clinical trials. No compounding pathway. No brand product. The only US channels are RUO vendors that the FDA has targeted with warning letters. Assume any sourcing carries significant regulatory and quality risk.
No suppliers in our directory currently stock this compound. For investigational or research-only compounds, legitimate channels may not exist outside clinical trials.
Browse full supplier directory§ 09 Safety
Safety & side effects
Side effects
- 01Nausea
- 02GI effects typical of incretin class
Contraindications
None specified.
§ 10 Questions
Survodutide FAQ
- What is Survodutide?
- Dual glucagon/GLP-1 receptor agonist from Boehringer Ingelheim; holds FDA Breakthrough Therapy designation for MASH with fibrosis. Survodutide is a weekly SC peptide that co-agonizes glucagon and GLP-1 receptors. Glucagon activity is proposed to raise hepatic energy expenditure while GLP-1 suppresses appetite, with particular rationale in metabolic-associated steatohepatitis (MASH).
- What is Survodutide used for?
- Reported uses include weight loss comparable to tirzepatide-class in phase 2, fda breakthrough therapy designation for mash (sept 2024), and hepatic fat reduction and fibrosis signal. Evidence strength is rated Clinical — see the evidence section for detail.
- How is Survodutide dosed?
- Commonly referenced dosing is 0.6 – 6 mg weekly (trial), administered SubQ. This is educational reference only; consult a licensed clinician before use.
- What are the side effects of Survodutide?
- Commonly reported side effects include nausea and gi effects typical of incretin class. This list is not exhaustive.
- Is Survodutide legal?
- Currently in active clinical trials. No compounding pathway. No brand product. The only US channels are RUO vendors that the FDA has targeted with warning letters. Assume any sourcing carries significant regulatory and quality risk. FDA status: Investigational. FDA Breakthrough Therapy designation (MASH)..
§ 11 References
Selected references
- 01
Phase 2 obesity
PMID: 37634188
- 02
Phase 2 MASH
PMID: 38856224
- 03
SYNCHRONIZE-1
NCT06066515